Literature DB >> 15702723

Rift Valley fever.

G H Gerdes.   

Abstract

Rift Valley fever (RVF) is an arthropod-borne viral disease of ruminants, camels and humans. It is also a significant zoonosis which may be encountered as an uncomplicated influenza-like illness, but may also present as a haemorrhagic disease with liver involvement; there may also be ocular or neurological lesions. In animals, RVF may be inapparent in non-pregnant adults, but outbreaks are characterised by the onset of abortions and high neonatal mortality. Jaundice hepatitis and death are seen in older animals. Outbreaks of RVF are associated with persistent heavy rainfall with sustained flooding and the appearance of large numbers of mosquitoes, the main vector. Localised heavy rainfall is seldom sufficient to create conditions for an outbreak; the simultaneous emergence of large numbers of first generation transovarially infected mosquitoes is also required. After virus amplification in vertebrates, mosquitoes act as secondary vectors to sustain the epidemic.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15702723     DOI: 10.20506/rst.23.2.1500

Source DB:  PubMed          Journal:  Rev Sci Tech        ISSN: 0253-1933            Impact factor:   1.181


  80 in total

1.  The nonstructural protein NSs induces a variable antibody response in domestic ruminants naturally infected with Rift Valley fever virus.

Authors:  José-Carlos Fernandez; Agnès Billecocq; Jean Paul Durand; Catherine Cêtre-Sossah; Eric Cardinale; Philippe Marianneau; Michel Pépin; Noël Tordo; Michèle Bouloy
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

2.  Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in Tanzania, 2007.

Authors:  Mohamed Mohamed; Fausta Mosha; Janeth Mghamba; Sherif R Zaki; Wun-Ju Shieh; Janusz Paweska; Sylvia Omulo; Solomon Gikundi; Peter Mmbuji; Peter Bloland; Nordin Zeidner; Raphael Kalinga; Robert F Breiman; M Kariuki Njenga
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

3.  Rift Valley Fever: scientific pathways toward public health prevention and response.

Authors:  Robert F Breiman; Bruno Minjauw; S K Sharif; Peter Ithondeka; M Kariuki Njenga
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

4.  Risk assessment of the introduction of Rift Valley fever from the Horn of Africa to Yemen via legal trade of small ruminants.

Authors:  Shaif Abdo-Salem; Agnès Waret-Szkuta; François Roger; Marie-Marie Olive; Khalid Saeed; Véronique Chevalier
Journal:  Trop Anim Health Prod       Date:  2010-10-22       Impact factor: 1.559

5.  Creation of a nonspreading Rift Valley fever virus.

Authors:  Jeroen Kortekaas; Nadia Oreshkova; Viviana Cobos-Jiménez; Rianka P M Vloet; Christiaan A Potgieter; Rob J M Moormann
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

Review 6.  Emerging Infections of CNS: Avian Influenza A Virus, Rift Valley Fever Virus and Human Parechovirus.

Authors:  Clayton A Wiley; Nitin Bhardwaj; Ted M Ross; Stephanie J Bissel
Journal:  Brain Pathol       Date:  2015-09       Impact factor: 6.508

7.  Using a field quantitative real-time PCR test to rapidly identify highly viremic rift valley fever cases.

Authors:  M Kariuki Njenga; Janusz Paweska; Rose Wanjala; Carol Y Rao; Matthew Weiner; Victor Omballa; Elizabeth T Luman; David Mutonga; Shanaaz Sharif; Marcus Panning; Christian Drosten; Daniel R Feikin; Robert F Breiman
Journal:  J Clin Microbiol       Date:  2009-01-26       Impact factor: 5.948

8.  A statistical model of Rift Valley fever activity in Egypt.

Authors:  John M Drake; Ali N Hassan; John C Beier
Journal:  J Vector Ecol       Date:  2013-12       Impact factor: 1.671

9.  Modelling vertical transmission in vector-borne diseases with applications to Rift Valley fever.

Authors:  Nakul Chitnis; James M Hyman; Carrie A Manore
Journal:  J Biol Dyn       Date:  2013       Impact factor: 2.179

10.  Prevalence of antibodies against Rift Valley fever virus in Kenyan wildlife.

Authors:  A Evans; F Gakuya; J T Paweska; M Rostal; L Akoolo; P J Van Vuren; T Manyibe; J M Macharia; T G Ksiazek; D R Feikin; R F Breiman; M Kariuki Njenga
Journal:  Epidemiol Infect       Date:  2007-11-08       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.